Miracell to Exhibit ‘Smart M-Cell’ at Korea Life Science Week 2024… “Leading the Global Stem Cell Treatment Field!”
Miracell Co., Ltd. (CEO Shin Hyun-soon) participated in “KOREA LIFE SCIENCE WEEK 2024 & KOREA LAB Autumn 2024,” held at COEX in Seoul from Tuesday, November 12th to Thursday, November 14th. With the goal of specializing in “safe stem cell therapy,” Miracell has consistently collaborated with domestic and international medical institutions on research and development (R&D) and has adopted advanced medical technologies.Based on its experience in stem cell research, which began in earnest in 2009, Miracell has introduced stem cell therapies, cosmetics, and medical devices for conditions such as severe limb ischemia (Buerger’s disease, diabetic foot, etc.), acute myocardial infarction, osteophytes, and osteoarthritis. Notably, last year, Miracell received certification as a new medical technology (Ministry of Health and Welfare) for its bone marrow stem cell injection therapy for knee osteoarthritis. At this exhibition, Miracell showcased its “Smart M-Cell,” a biomedical device that collects stem cells from bone marrow and blood. This device was previously designated and certified as an innovative medical device and a New Excellent Technology (NET), demonstrating its outstanding competitiveness.Functioning on a principle similar to a centrifuge, the Smart M-Cell selectively and effectively extracts and concentrates stem cells, red blood cells, white blood cells, platelets, and growth factors.Company officials explained that the cells obtained using this method can be highly utilized in personalized treatments. Compared to autologous platelet-rich plasma (PRP) devices commonly used in the medical field, Miracell can handle significantly larger volumes of bone marrow and blood simultaneously. As the sample volume increases, the number of effective cells obtained also increases proportionally. It has also proven its superior extraction efficiency across various criteria. A Miracell representative stated, “We are leading the global development of stem cell therapy and advanced regenerative medicine by gradually expanding the global supply of Smart Mcell, as well as BmSC and BSC kits developed based on our original technology.” “Stem cell therapy is gaining recognition as a treatment option to improve human health and quality of life, particularly in developed countries, addressing the rapidly aging population. Therefore, interest and expectations for our company are growing.” The company continued, “Miracell plans to successfully complete US FDA approval for its BmSC kit, currently in the process, and establish itself as a world-class company in the stem cell market.” “Furthermore, as one of the leading companies in Korea’s biotechnology industry, our goal is to continue to grow.” Meanwhile, Korea Life Science Week 2024, held in conjunction with KOREA LAB Autumn 2024 (International Research Experiment and R&D Convergence Advanced Science and Technology Exhibition), showcased the latest technologies and products in the fields of pharmaceuticals and biohealth, advanced biotechnology, regenerative medicine, convergence medical technology, experimental and analytical equipment, and research and development (R&D) equipment. Furthermore, various forums and seminars were held concurrently, where industry experts and researchers discussed the latest technological trends and strategies. Source: AVING (https://kr.aving.net)